Skip to main content

Evrysdi

Generic name: risdiplam
Dosage form: oral solution
Drug class: Miscellaneous uncategorized agents

Medically reviewed by Judith Stewart, BPharm. Last updated on May 31, 2022.

What is Evrysdi?

Before taking Evrysdi

Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Evrysdi?

See the detailed Instructions for Use that comes with your prescription for information on how to take or give Evrysdi oral solution.

Taking Evrysdi

Reusable Oral Syringes

Evrysdi side effects

The most common side effects include:

These are not all of the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Evrysdi?

Keep Evrysdi and all medicines out of the reach of children.

General information about the safe and effective use of Evrysdi.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Evrysdi?

Active ingredient: risdiplam
Inactive ingredients: ascorbic acid, disodium edetate dihydrate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, sucralose, and tartaric acid.

Popular FAQ

Evrysdi (risdiplam) and Spinraza (nusinersen) work in different ways to increase the level of functional SMN (survival of motor neuron) protein in people with spinal muscular atrophy (SMA). A key difference between the two drugs is that Evrysdi is taken orally, whereas Spinraza needs to be given via intrathecal injection. Continue reading

Evrysdi (risdiplam) works by targeting the SMN2 gene (survival motor neuron gene 2), causing it to make more functional SMN protein. This increases SMN protein levels throughout the central nervous system and body, helping to improve motor nerve and muscle function in children and adults with SMA. Continue reading

Several major trials have reported that Evrysdi significantly improves survival motor neuron (SMN) protein levels in newborns, children, and adults with SMA, allowing an increase in muscle strength and the achievement of milestones, such as being able to sit independently for 5 or more seconds at a time. Continue reading

Evrysdi does not cure spinal muscular atrophy (SMA), it just replaces a protein that is low or missing in children or adults with the condition, improving muscle strength and allowing some relief from some of the symptoms of SMA. Evrysdi must be taken for a person’s lifetime; if Evrysdi is stopped the newborn, child, or adult’s SMA symptoms will progressively worsen at a faster rate. Continue reading

Evrysdi (risdiplam) is an oral solution that is administered via an oral syringe. It can be given orally or via a gastrostomy or nasogastric tube. Continue reading

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.